KUAISHOU-W
01024
BILIBILI-W
09626
BOSS ZHIPIN-W
02076
BIDU-SW
09888
BEKE-W
02423
HK Stock MarketDetailed Quotes
01672 ASCLETIS-B
- 7.150
- +0.050+0.70%
Trading Mar 7 10:15 CST
6.88BMarket Cap-24.32P/E (TTM)
7.180High6.970Low605.00KVolume7.130Open7.100Pre Close4.27MTurnover0.06%Turnover RatioLossP/E (Static)962.08MShares7.77052wk High2.88P/B6.88BFloat Cap0.76052wk Low--Dividend TTM962.08MShs Float14.900Historical High--Dividend LFY2.96%Amplitude0.760Historical Low7.052Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
ASCLETIS-B News
Hong Kong stock movement | ASCLETIS-B (01672) rose over 5%. ASC30 and ASC47 both have differentiated design methods, and the future of product development is promising.
ASCLETIS-B (01672) rose over 5%, with a current increase of 5.43%, priced at 7.34 Hong Kong dollars, with a transaction volume of 23.9981 million Hong Kong dollars.
[Brokerage Focus] China Securities Co.,Ltd. maintains a "Buy" rating on Gilead Sciences (01672), indicating that weight loss and lipid-lowering drugs are promising for the future.
Jinwu Financial News | China Securities Co.,Ltd. Research Reports indicate that Gilead Sciences (01672) announced that its GLP-1R agonist ASC30 has achieved positive results in Phase Ib clinical trials in the USA. Data shows that after calibration with the placebo group, ASC30 led to a weight loss of 4.2% and 6.2% respectively in the first two cohorts, and its safety profile is good. The firm believes that the Global weight loss drug market is growing rapidly, with many overweight or obese adults in urgent need of Innovative Drugs to improve and enhance their quality of life. Based on this, the company's two drugs, ASC30 and ASC47, both have differentiated design approaches, and product development is underway.
ASCLETIS-B (1672.HK): Early clinical research has made breakthroughs. GLP1 oral medications are worth paying attention to.
The company announced that its GLP-1R agonist ASC30 has achieved positive results in Phase Ib clinical trials in the USA. Data show that after calibration against the placebo group, ASC30 resulted in a weight loss of 4 in the first two cohorts.
Express News | Most pharmaceutical stocks in the Hong Kong market strengthened, with ALPHAMAB-B rising over 13%.
The Hong Kong stock market for Medical stocks is surging! In February, the strongest has risen over 220%, what happened?
Recently, the General Office of the State Council forwarded the "2025 Action Plan for Stabilizing Foreign Investment" from the Ministry of Commerce and the National Development and Reform Commission, promoting the orderly opening of the Biomedical sector.
Hong Kong Stock Movement | ASCLETIS-B (01672) rises over 7% as Institutions indicate the company has abundant catalysts in weight loss & diabetes control this year.
ASCLETIS-B (01672) rose over 7%, as of the time of writing, it increased by 7.42%, trading at 6.37 Hong Kong dollars, with a transaction volume of 13.2206 million Hong Kong dollars.
[Brokerage Focus] HAITONG SEC has initiated a rating of "Outperform" for Geren Pharmaceuticals (01672). Its weight loss & diabetes Innovative Drugs are both at the forefront of Global progress.
Jingwu Financial News | HAITONG SEC released a Research Report indicating that in 2025, Galen Pharmaceuticals (01672) will have rich catalyst readouts in the weight loss and diabetes fields. The firm is Bullish on the global competitiveness of its pipelines ASC30 and ASC47, and recommends following the company's progress. Currently, the company's pipelines in the weight loss and diabetes fields at the clinical stage include the oral and subcutaneous small molecule GLP1R agonist ASC30, as well as the fat-targeting small molecule THRβ injection ASC47. The firm determines that innovative drugs focused on multiple targets, oral administration, long-acting effects, and muscle gain with fat loss are key directions in the Global weight loss market.
ASCLETIS-B (1672.HK): In 2025, the company has abundant catalysts in the weight loss & blood sugar reduction fields. It is recommended to pay attention to the company's progress.
In 2025, the company has rich catalysts in the weight loss & diabetes field, and we are Bullish on the global competitiveness of its pipelines ASC30 and ASC47, suggesting to pay attention to the company's progress. Currently, the company's clinical stages in the weight loss & blood sugar reduction fields are.
Hong Kong stocks in the Medical sector have surged against the trend, with "AI + Medical" becoming the NEW FOCUS AUTO of market attention.
Currently, "AI + Medical" is becoming a NEW FOCUS AUTO for market attention. Several Brokerage Institutions believe that the application value of AI in areas such as drug development, auxiliary diagnosis, and medical data analysis is underestimated, and by 2025, "AI + Medical" may encounter significant development opportunities.
Hong Kong stocks closed (02.20) | The Hang Seng Index fell 1.6%, with major Technology stocks collectively declining, while some pharmaceutical stocks strengthened against the trend.
Hong Kong stocks showed a significant correction today, with the Hang Seng Index and the China Enterprises Index both falling over 2% at one point, while the Science and Technology Index closed down over 3%.
Intra-day surge of 36%! Garri Pharmaceutical announces positive progress in the phase Ib trial of the GLP-1R weight loss drug, with industry focus on the method and duration of administration.
① The interim results of the MAD study for ASC30 from Gilead Sciences showed a weight loss of 4.3% and 4.2% in the two MAD cohorts; ② ASC30 can be administered orally once a day or through subcutaneous injection once a month, but the industry believes that further clinical trials are needed to demonstrate its potential; ③ A breakthrough in domestic weight loss medications may be expected in 2025.
Hong Kong Stock Market Review | Hang Seng Index dropped 1.38% in the morning, while most CRO Concept stocks rose.
Most Concept stocks related to CRO have risen, and the Industry is expected to enter a stable growth phase. AI pharmaceutical technology and others are worth paying attention to.
After running out of medicines and with the stock price nearly at "zero", is Gilead Sciences ready for a "desperate counterattack"?
Risen for six consecutive months.
Ge Li Pharmaceutical (01672.HK) surged over 30% as weight loss medication achieved positive mid-term results.
Gele Pharmaceuticals (01672.HK) opened high today (on the 20th) with a rise of 14.82%, and the increase expanded, reaching a maximum of 6.34 HKD. It currently reports at 6.33 HKD, up 32.15%, with a trading volume of 12.3135 million shares, involving 73.6717 million HKD. Gele Pharmaceuticals announced that the first two cohorts of the multi-dose escalation study of the small molecule oral GLP-1R agonist ASC30 in the USA Phase Ib trial have obtained positive interim results. The ASC30 developed by the company is the first and only small molecule GLP-1 receptor (GLP-) that can be taken orally once daily or injected subcutaneously once a month for the treatment of obesity.
Express News | Most pharmaceutical stocks in Hong Kong have risen, with ASCLETIS-B increasing by over 27%.
Event Update | Gilead Sciences surged over 20% in early trading, with ASC30 achieving positive interim results in obesity research.
Gilead Pharmaceuticals opened nearly 15% higher, as of the time of writing, up 20.67%, reported at 5.78 Hong Kong dollars, with a turnover of 13.839 million Hong Kong dollars.
Announcement selection | UBTECH plans to allocate and issue 10.1551 million new Listed in Hong Kong shares, net raising 0.876 billion Hong Kong dollars; HUISHANG BANK is expected to earn a net profit of 15.9 billion yuan in 2024.
LC LOGISTICS expects its annual profit to more than double; Manulife Financial recorded a core profit of 7.2 billion Canadian dollars in 2024.
Insiders Of Ascletis Pharma Are Up 204% On Their CN¥16.2m Purchase
Hong Kong Stock Morning Report | Two departments encourage foreign investment to conduct Private Equity in China. Meituan will pay social insurance for full-time and stable part-time delivery riders.
① Two departments: Encouraging foreign investment to engage in Private Equity in China, guiding more high-quality foreign capital to invest long-term in our listed companies. ② State-owned Assets Supervision and Administration Commission: Accelerating the establishment of an evaluation system for state-owned enterprises to fulfill their Global Strategy missions. ③ Meituan: Will provide social insurance for full-time and stable part-time delivery riders. ④ Federal Reserve minutes: Interest rate cuts require further decline in inflation, and tariff policies add uncertainty.
ASCLETIS-B (01672) announced that the first two cohorts of the Phase Ib multiple ascending dose study of the small molecule oral GLP-1R agonist ASC30 in the USA have achieved positive interim results.
ASCLETIS-B (01672) announced that ASC30 is being developed in the USA as a once-daily oral tablet for the treatment of obesity...
Trending Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.
